Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis.

Authors: Brown, R  Kabani, K  Favaloro, J  Yang, S  Ho, PJ  Gibson, J  Fromm, P  Suen, H  Woodland, N  Nassif, N  Hart, D  Joshua, D 
Citation: Brown R, etal., Blood. 2012 Sep 6;120(10):2055-63. doi: 10.1182/blood-2012-03-416792. Epub 2012 Jun 15.
Pubmed: (View Article at PubMed) PMID:22705596
DOI: Full-text: DOI:10.1182/blood-2012-03-416792

The transfer of membrane proteins between cells during contact, known as trogocytosis, can create novel cells with a unique phenotype and altered function. We demonstrate that trogocytosis is more common in multiple myeloma (MM) than chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia; that T cells are more probable to be recipients than B or natural killer cells; that trogocytosis occurs independently of either the T-cell receptor or HLA compatibility; and that after trogocytosis, T cells with acquired antigens can become novel regulators of T-cell proliferation. We screened 168 patients with MM and found that CD86 and human leukocyte antigen G (HLA-G) were antigens commonly acquired by T cells from malignant plasma cells. CD3+ CD86acq+ and CD3+ HLA-Gacq+ cells were more prevalent in bone marrow than peripheral blood samples. The presence of either CD86 or HLA-G on malignant plasma cells was associated with a poor prognosis. CD38++ side population cells expressed HLA-G, suggesting that these putative myeloma stem cells could generate immune tolerance. HLA-G+ T cells had a regulatory potency similar to natural Tregs, thus providing another novel mechanism for MM to avoid effective immune surveillance.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11354971
Created: 2016-08-01
Species: All species
Last Modified: 2016-08-01
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.